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Abstract Puberty suppression by means of gonadotropin
releasing hormone (GnRH) analogs is considered a diagnostic aid
ingenderdysphoricadolescents.However, therearealsoconcerns
about potential risks, such as pooroutcome or post-surgical regret,
adverse effects on metabolic and endocrine status, impaired incre-
mentofbonemass, and interferencewithbraindevelopment.This
case report is on a 22-year follow-up of a female-to-male trans-
sexual, treated with GnRH analogs at 13 years of age and con-
sidered eligible for androgen treatment at age 17, and who had
gender reassignment surgery at 20 and 22 years of age. At follow-
up, he indicated no regrets about his treatment. He was function-
ing well psychologically, intellectually, and socially; however, he
experienced some feelings of sadness about choices he had made
ina long-lasting intimaterelationship.Therewerenoclinicalsigns
of a negative impact on brain development. He was physically in
good health, and metabolic and endocrine parameters were within
reference ranges. Bone mineral density was within the normal
range for both sexes. His final height was short as compared to
Dutch males; however, his body proportions were within normal
range.Thisfirst reporton long-termeffectsofpubertysuppression
suggests that negative side effects are limited and that it can be a
useful additional tool in the diagnosis and treatment of gender
dysphoric adolescents.
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Introduction
In 1998, a case study was published describing the use of a
gonadotropin releasing hormone (GnRH) analog to suppress
puberty of a 13-year-old gender-dysphoric girl (Cohen-Kettenis
& van Goozen, 1998). At age 16, she was referred to a gender
identity clinic where a diagnosis of gender identity disorder
(GID)wasmade.Shewasconsideredeligible forandrogen treat-
ment at age 17, but chose to delay the therapy and social transi-
tioning until she was 18 years old, because she first wanted to
finish high school. Subsequently, she had gender reassignment
surgery. This case illustrated that puberty suppression may be
useful as an additional tool in the diagnosis and treatment of
young gender dysphoric adolescents and that, for certain ado-
lescents with a life-long consistent and extreme GID, it may be a
physically and psychologically beneficial way to intervene.
Since thisfirstcase,GnRHanalogprescriptionhasbeen intro-
ducedasapartofanextendeddiagnosticphaseonamore regular
basis at the Dutch clinic where she had been treated. The way it
was used in the diagnostic protocol has been described in detail
elsewhere (Cohen-Kettenis & Pfa¨fflin, 2003; Cohen-Kettenis &
Delemarre-van de Waal, 2006). In the last decade, puberty sup-
pression has become part of the gender reassignment procedure
in a number of clinics in European countries, Australia, Canada,
and the U.S.
As has been argued previously, puberty suppression in gen-
der dysphoric adolescents has a number of advantages (Cohen-
Kettenis,Delemarre-vandeWaal,&Gooren,2008;Wren,2000).
First, it may relieve the suffering that stems from a discrep-
ancybetweenone’sassignedandexperienced/expressedgender,
which can adversely affect one’s social development and school
career. Second, adolescents and mental health professionals
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‘‘buy’’time, which enables them to explore the adolescents’ gen-
der identitydevelopmentandtheirdesireforgenderreassignment.
Third, GnRH analog treated adolescents with persisting GID will,
as adults, have fewer problems in passing in the new gender than
untreated adolescents, which may contribute to better adjustment
(Nuttbrocketal., 2010;Ross&Need,1989).Fourth,pubertal sup-
pression makes certain forms of surgery redundant or less inva-
sive.Fifth,unfavorablepostoperativeoutcomeseemstobeassoci-
ated with a late rather than an early start of gender reassignment
(for reviews, see Cohen-Kettenis & Gooren, 1999; Pfa¨fflin &
Junge,1992).Sixth,youthwithoutaccess to this treatmentmay
try to find illicit sources of medication (e.g., the Internet).
Resistance to pubertal suppression also exists. Some con-
sider it impossible to make a definitive diagnosis of GID in
adolescence, because they believe that gender identity may still
be fluctuating during this developmental phase (Korte et al.,
2008; Viner, Brain, Carmichael, & Di Ceglie, 2005). However,
GIDinadolescenceappears tobehighlypersistent.At theDutch
gender identity clinic, none of the adolescents diagnosed with
GID and treated with GnRH analogs refrained from further
treatment procedures or regretted gender reassignment. Those
who could not start treatment immediately after completion of
the diagnostic procedure because of serious risk factors did not
refrain from pursuing gender reassignment later. They usually
started treatment after the other issues had been addressed,
which was, in some cases, in early adulthood.
Another important point of criticism concerns the physical
consequences of GnRH analogs on the development of bone
mass, growth, and brain development. The first data of a Dutch
cohort of adolescents who had been treated with GnRH analogs
suggest that, after an initial slowing in bone accretion, it sig-
nificantly caught up after the commencement of cross-sex ste-
roid hormone treatment (Delemarre-van de Waal & Cohen-
Kettenis,2006).Bodyproportions,asmeasuredbysittingheight
and sitting-height/height ratio, remained in the normal range.
With regard to height, for both genders, stature could be influ-
enced hormonally to become more in the range of the desired
sex (Delemarre-van de Waal & Cohen-Kettenis, 2006).
Since most of the adolescents who were treated with GnRH
analogs are still in their early 20 s, psychological and physical
long-term effects of puberty suppression are not known. This
report is the first very long-term follow-up (22 years) of a natal
female, now 35 years old, who underwent pubertal suppression
and subsequent gender reassignment. He read the report and
provided us with a letter of consent to publish it.
Case Report
First Follow-Up: Psychosocial Information
In the 1998 report on the treatment of B, he was 20 years old. B
had been a child with a classical gender dysphoric development
and fulfilled the current criteria for GnRH analog treatment eli-
gibility.He was interviewed shortlyafterhis legalgenderchange.
This meant that he had had puberty suppression, cross-sex hor-
mone treatment, a mastectomy, ovariectomy, and uterus extir-
pation. From his assessment during the diagnostic phase, he
appeared to be an intelligent person (IQ = 128) with excellent
problem-solving capabilities with respect to emotional matters.
Vulnerable aspects of his psychological functioning were his
insecurityabouthimselfandmoderatelydepressed feelings. Inall
other areas, his scores on a broad range of measures were in the
average range, as compared to Dutch normative samples. Shame
concerning his transsexualism made him highly selective in his
friendships and guarded in his contacts with new people. At the
assessment, 1 year after his ovariectomy but prior to his meta-
idoioplasty, he no longer reported feelings of gender dysphoria.
He had adjusted easily to the male role and expressed no doubts
on the adequacy of his masculine behavior. After the develop-
ment of his secondary male sex characteristics, nobody had ever
approached him as a woman. He never felt any regrets about his
decisionandhadnevercontemplatedlivingasagirlagain.Know-
ing what gender reassignment implied, he would do it all over
again. B was happy with his life and did not feel lonely. He
showedasignificantpre-post treatmentdecrease in his feelings
of inadequacy. At the time, he was attending medical school.
First Follow-Up: Medical Information
B attended the pediatric endocrinology clinic for the first time
when he was age 13.7 years. His medical history was unevent-
ful. Puberty had started 1–2 years previously, but menarche had
not occurred. On physical examination, a healthy girl was seen
with a height of 157.3 cm and a Tanner pubertal stage of B3, P3.
Bone age according to Tanner and Whitehouse was 13.5 years.
Targetheight, asafemale,wasestimatedat171 cm,basedonthe
parental height. Puberty suppression was induced by the GnRH
analog Triptorelin, in a dose of 3.75 mg every 4 weeks intra-
muscularly. On this dosage, B steadily kept on growing.
Atage18.6 years,hisheightwas 165.8 cm. Inductionofmale
puberty and accompanying secondary male sex characteristics
was initiated by administration of 100 mg testosterone-ester
mixture intramuscularly every 2 weeks. This was, after 6 months,
increased to 250 mg testosterone-ester mixture, every 2–3
weeks intramuscularly. At the start of the androgen treatment,
the Triptorelin treatment was discontinued.
When B was 20 years old, he had a subcutaneous mastec-
tomy by way of an infra-areolar approach, a few months later
followed by a hysterectomy and gonadectomy. Two years later,
metaidoioplasty and testes implantation were performed.
Second Follow-Up: Psychosocial Information
Fifteen years after the first interview and testing session, at age
35, B was seen again at the clinic. He lived on his own and he
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worked as a family doctor in private practice with two col-
leagues. All family members knew about his transitioning as did
some of his friends. He was very satisfied about his circle of
friends and had never been treated negatively because of his
transsexualism.
Bwasstill satisfiedabouthis (minor)breast surgery,hisovar-
iectomy, and his hysterectomy, but no longer about the meta-
idoioplasty he underwent one year after the first follow-up
session. He did not like its size and shape and he could hardly
urinate in a standing position. He was able to have orgasms, but
he could not have sexual intercourse. Because of his desire to
have more convincingly male appearing external genitals and
his wish to be able urinate in a standing position, he considered
having a phalloplasty. Despite his good looks and very mascu-
line appearance, he had not had many steady girlfriends, which
may have resulted from the guardedness he already had as
an adolescent. At age 29, he had a serious relationship with a
woman, which lasted for 5 years. However, he chose not to live
together when the opportunity to do so arose. After his choice to
continue living apart, his girlfriend ended the relationship, a few
months before his interview at the clinic. This made him very
much regret his lack of commitment. B considered it likely that
his need to distance himself from her had been related to his
shame about his genital appearance and his feelings of inade-
quacy in sexual matters. Additional factors, such as serious ill-
ness of his father and a suicide among his sisters’ in-laws, made
him rather sad at the time of the interview. Although his psy-
choneuroticism score on the Symptom Checklist-90 (Arrindell
& Ettema, 2003) was in the normal range, his depression sub-
score was high, indicating depressed feelings. However, on the
Beck Depression Inventory, he scored in the ‘‘minimal range’’
(van der Does, 2002), indicating that he did not fulfill criteria
for clinical depression. On the Adult Self-Report, assessing
adaptive functioning and problems in adults aged 18-59 years
(Achenbach & Rescorla, 2003), all his scores were in the
normal range.
It seems, therefore, that B functioned well in most aspects of
life,but thathewasstillstrugglingwiththequestion,howtohandle
the dissatisfaction and shame about his genital appearance.
Second Follow-Up: Medical Information
At age 35, on physical examination, we saw a healthy and well
virilized person. Blood pressure was 120/85 mmHg, final height
was 169.5 cm and weight was 73 kg, which resulted in a body
mass index (BMI) of 25.4 kg/m2. Sitting height was 88 cm. Skull
circumference was 55.5 cm. For a comparison of his anthro-
pometrical measurements to the normal reference values of
Dutch males and females, see Table 1.
Test Results
A fasting venous blood sample was drawn. General health
markers, like hematological parameters (Hb, ht, erythrocytes),
renal function,and liverenzymes,wereallwithin thenormal ref-
erence value ranges. His lipid profile showed a total cholesterol
level of 228.3 mg/dl (\251.5 mg/dl), LDL-cholesterol 154.8 mg/
dl (\193.5 mg/dl), HDL-cholesterol 55.0 mg/dl ([34.8 mg/dl),
andtriglycerides97.4 mg/dl (\177 mg/dl).Hisglucosevaluewas
97.3 mg/dl (\144.1 mmol/l) with an insulin level of 21 pmol/l
(12–96 pmol/l for a fasting sample). His HbA1c was 5.4% (4.3–
6.1%). These values were in the normal range.
With respect to the gonadal axis, a normal-low serum tes-
tosterone level of 236.6 ng/dl (231–866 ng/dl) was found. This
relatively low level was probably due to the fact that the blood
sample was taken just before the next testosterone-ester mixture
injection. Gonadotropins were elevated as a consequence of the
gonadectomy. LH and FSH were 16 U/l and 50 U/l, respec-
tively. Additionally determined endocrine parameters, such as
thyroid and adrenal function, were all within normal reference
ranges.
With respect to bone mineral density (BMD), a dual energy
X-ray absorptiometry (DEXA) scan was performed to deter-
mine B’s BMD in the lumbar spine, the non-dominant hip, and
(further) total body. The observed values were related to the
bone peak mass for white females and for white males, resulting
in T-scores. For all values, the z-score was determined as well
(see Table 2).
Table 1 B’s anthropometrical measurements at the time of his last visit to our outpatient clinic (age 35) compared to Dutch reference values for both
sexes
B SD females P50 females SD males P50 males
Height (cm) 169.5 -0.16 170.56 -2.03 183.86
Weight (kg) 73 0.95 63.85 -0.24 75.28
Sitting height (cm) 88 -0.47 89.63 -1.94 94.65
Sitting height/height ratio 0.519 -0.47 0.5260 0.02 0.5130
Skull circumference (cm) 55.5 0.13 55.29 -1.32 57.82
BMI (kg/m2) 25.4 1.93 22.90 1.90 22.11
SD standard deviation, P50 50th percentile
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Discussion
The case of B is the first in the literature to show the long-term
results of puberty suppression and subsequent hormonal and
surgical intervention in a consistently gender dysphoric youth.
Suppression of puberty in adolescents should be done only
after careful diagnostic work by specialists in the field. Giving
informed consent is a crucial aspect of the procedure. In order
to give valid consent, the adolescent should have, as completely
as possible, information about known and unknown aspects of
the treatment. In the case of B, it was not possible to give the
13 yearadolescentmuch information on the long-termeffectsof
GnRH analog treatment in physically healthy young people.
Yet,Bwascertain thathedidnotwantanyfurtherpubertaldevel-
opment and very deliberately decided to start with the GnRH
analogs. For a number of years, still living in the female role, B
took the opportunity to figure out whether he truly wanted to
have gender reassignment, knowing that this would not be an
easy life. Although he tended to be embarrassed about his gen-
der dysphoria, especially in the beginning of the process, he has
always been quite clear about his feeling that he could not live
further as a girl. Twenty-two years after this decision, he still is
convinced that his choice to live as a man was the right one.
The concern of many clinicians that halting puberty for a
number of years would involve unacceptable health risks turned
out not to be true for B. All observed anthropometric measure-
ments were within the normal range (50th percentile ±2 SD) for
biological females. Also, B’s final height was within the target
height range for females. When compared to natal males, how-
ever,B’sfinalheightwas justbelow-2SD. Inallother respects,
B’s anthropometric values were in the low-normal male range.
It is noteworthy to realize that the normal values we have used
came from Dutch population studies. As B is half Italian, they
could also be compared to values for inhabitants from Italy,
which deviate from those of the Dutch normal population. The
50th percentile values for height for the Italian population are
163.2 cm and 176.9 cm for females and males, respectively
(Cacciari et al., 2002). As B’s sitting height/height ratio is near
the 50th percentile for both sexes, B’s body proportion is within
the normal range. Blood tests showed increased serum levels
of FSH and LH, which was due to his gonadectomy. B’s lipid
profile did not deviate from the normal reference values and the
BMD measurements showed values well above the 50th per-
centile for biological females. Compared to reference values for
white males, his BMD values were around the 50th percentile.
Although B would have liked to be taller, we did not find
unfavorable medical outcomes. Therefore, the fear that GnRH
analog treatment will result in poor long-term outcome was not
supported in thiscase. Nonetheless, long-termfollow-upstudies
on larger cohorts of transgender adults treated with GnRH
analogs are needed to support this finding.
Although gender reassignment is highly effective in reliev-
ing gender dysphoria (Cohen-Kettenis & Gooren, 1999; Gijs &
Brewaeys, 2007; Pfa¨fflin &Junge, 1992), it is no panacea. Espe-
cially in the area of intimate relationships, it may remain diffi-
cult to find a suitable partner and overcome one’s own barriers,
as is shown in the case of B.
Pubertal suppression, however, averts the despair of gender
dysphoric adolescents because of their physical changes and it
may contribute to more self-confidence when socially interact-
ing in adolescence and adulthood. On a day-to-day basis, B did
not have to explain himself or defend his choices. He was not
harassed or stigmatized. The case of B gives hope that negative
side effects of puberty suppression are limited, although the
results will have to be confirmed in further studies. With regard
to the psychological functioning of puberty suppressed and sub-
sequently gender reassigned individuals, a relatively favorable
outcome (at least one year post-surgery) was also recently
reported (de Vries, 2010). This and B’s second follow-up again
illustrate that puberty suppression can be a useful additional tool
in the diagnosis and treatment of gender dysphoric adolescents.
This view is supported in the recently published guidelines of
the Endocrine Society on the treatment of transsexual persons
(Hembree et al., 2009).
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